National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF)

Liver disease deaths are rising, but transplants remain scarce in India. With over 100,000 needed annually and only \~2,500 performed, non-transplant options are urgently needed. Regenerative therapy, especially MSCs, shows promise but lacks validation, particularly for non-viral Acute on Chronic Liver Failure (ACLF). The proposed NC-CHRM aims to develop and validate MSC-based therapy to promote native liver regeneration and offer a safe, effective, transplant-free treatment.

NCT Number	NCT07131540
Lead Sponsor	Institute of Liver and Biliary Sciences, India Collaborators: Indian Council of Medical Research
Conditions	Acute-On-Chronic Liver Failure
Enrollment	10 participants
Start Date	2026-01
Primary Completion	2031-12 (estimated)
Study Completion	2031-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-28